How much does a box of domestic ibrutinib/ibrutinib cost in the market?

Ibrutinib/Ibrutinib (Ibrutinib) is a selective BTK inhibitor and a targeted therapy drug. It has been approved in China and included in the medical insurance management. The main indications include Chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), chronic graft-versus-host disease, Waldenstrom's macroglobulinemia (WM) patients. BTK inhibitors can precisely block the B cell receptor signaling pathway, thereby inhibiting abnormal B cell proliferation and tumor growth, achieving disease relief and improving quality of life.

In the domestic market, the specifications of the original ibrutinib drug are usually 140 mg × 90 tablets, with a price of about more than 10,000 yuan per box. It has been included in Class B medical insurance, and the scope of reimbursement is limited to patients who meet the indications. The original drug has clear data support in terms of clinical efficacy and safety, and is an important choice for long-term treatment of patients. At the same time, domestic generic drugs have begun to be developed and sold. The ingredients and specifications of the drugs are basically the same as those of the original drugs, but the prices may be more advantageous. Since domestic generic drugs have been on the market for a short time, market supply and price information are still being dynamically adjusted.

For patients, the use of ibrutinib requires compliance with medical advice, regular follow-up of blood indicators and liver and kidney function, and attention to potential side effects, such as bleeding tendencies, infection risks, or abnormal heart rhythms. Long-term scientific medication not only helps maintain disease control, but also improves patients’ quality of life. With the promotion of domestic generic drugs, patients can choose more economical treatment options in the future while enjoying similar efficacy to the original drugs. Ibrutinib remains a core targeted drug in the treatment of B cell malignant diseases, and its accessibility and treatment continuity are gradually being optimized to provide a stable long-term management plan for more patients.

Reference materials:https://www.imbruvica.com/